Shandong Luoxin Pharmaceutical Group Stock Co. Technographics

Discover the latest software purchases and digital transformation initiatives being undertaken by Shandong Luoxin Pharmaceutical Group Stock Co. and its business and technology executives. Each quarter our research team identifies on-prem and cloud applications that are being used by the 1000 Shandong Luoxin Pharmaceutical Group Stock Co. employees from the public (Press Releases, Customer References, Testimonials, Case Studies and Success Stories) and proprietary sources.

During our research, we have identified that Shandong Luoxin Pharmaceutical Group Stock Co. has purchased the following applications: and the related IT decision-makers and key stakeholders.

Our database provides customer insight and contextual information on which enterprise applications and software systems Shandong Luoxin Pharmaceutical Group Stock Co. is running and its propensity to invest more and deepen its relationship with or identify new suppliers as part of their overall Digital and IT transformation projects to stay competitive, fend off threats from disruptive forces, or comply with internal mandates to improve overall enterprise efficiency.

We have been analyzing Shandong Luoxin Pharmaceutical Group Stock Co. revenues, which have grown to $250.0 million in 2024, plus its IT budget and roadmap, cloud software purchases, aggregating massive amounts of data points that form the basis of our forecast assumptions for Shandong Luoxin Pharmaceutical Group Stock Co. intention to invest in emerging technologies such as AI, Machine Learning, IoT, Blockchain, Autonomous Database or in cloud-based ERP, HCM, CRM, EPM, Procurement or Treasury applications.